Recent developments in toxic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 2, 2002, Pages 155-163

  Wali, Ravinder K ^a   Henrich, William L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN; INDINAVIR; MESALAZINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; RECOMBINANT CYTOKINE; RECOMBINANT INTERFERON; ROFECOXIB; SALAZOSULFAPYRIDINE;

CHINESE HERB; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DRUGS, CHINESE HERBAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERONS; ISOENZYMES; KIDNEY DISEASES; MEMBRANE PROTEINS; MUSHROOM POISONING; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFASALAZINE;

EID: 0036191775     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200203000-00005     Document Type: Review

References (48)

1. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study
2. Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis
3. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
4. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
5. Effects of celecoxib and naproxen on renal function in the elderly
6. Effects of celecoxib and naproxen on renal function in chronic renal insufficiency patients
7. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomized, controlled trial
8. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
9. Renal aspects of treatment with conventional nonsteroidal antiinflammatory drugs versus cyclooxygenase-2-specific inhibitors
10. Are selective COX-2 inhibitors nephrotoxic?
11. Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells
12. Relationship between nonphenacetin combined analgesics and nephropathy: A review
13. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic
14. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
15. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
16. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database
17. Renal and urologic complications of inflammatory bowel disease
18. Mesalazine-associated interstitial nephritis: Twice in the same patient
19. 5-Aminosalicylic acid (5ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: Is there a link?
20. Urothelial lesions in Chinese-herb nephropathy
21. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)
22. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: Could different components of aristocholic acids cause a different type of Chinese herb nephropathy?
23. Outbreak of Chinese herb nephropathy in Japan: Are there any differences from Belgium?
24. Cancer and herbs
25. Renal toxicity of protease inhibitors
26. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir
27. Crystalluria and urinary tract abnormalities associated with indinavir
28. Pyuria in patients treated with indinavir is associated with renal dysfunction
29. Incidence and risk factors for the development of indinavir-associated renal complications
30. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion
31. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin
32. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998
33. Incidence and associations of acute renal failure complicating high-dose intravenous immunogiobulin therapy
34. Wild-mushroom intoxication as a cause of rhabdomyolysis
35. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy
36. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy
37. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon
38. Renal thrombotic microangiopathy associated with interferon-alpha treatment of chronic myeloid leukemia
39. Reversible renal failure in a patient with the hypereosinophilia syndrome during therapy with alpha interferon
40. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: Coincidence or true side effect?
41. Thrombotic microangiopathy: A new dose-limiting toxicity of high-dose sequential chemotherapy
42. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis
43. Intravenous immunoglobulin protects against experimental thrombotic microangiopathy
44. Sodium loading treatment for amphotericin B-induced nephrotoxicity
45. Lipid formulations of amphotericin B
46. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
47. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
48. Antifungal compounds: Controversies, queries and conclusions